Cargando…

Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?

OBJECTIVE: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. SUBJECTS AND METHODS: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Penna, Gustavo Cancela e, Costa, Camila Teixeira, Pires, Magda Carvalho, Nunes, Tarcizo Afonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528568/
https://www.ncbi.nlm.nih.gov/pubmed/34591407
http://dx.doi.org/10.20945/2359-3997000000402
_version_ 1785111279268003840
author Penna, Gustavo Cancela e
Costa, Camila Teixeira
Pires, Magda Carvalho
Nunes, Tarcizo Afonso
author_facet Penna, Gustavo Cancela e
Costa, Camila Teixeira
Pires, Magda Carvalho
Nunes, Tarcizo Afonso
author_sort Penna, Gustavo Cancela e
collection PubMed
description OBJECTIVE: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. SUBJECTS AND METHODS: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 years and ≥ 55 years, sex, family history of thyroid cancer, history of irradiation, nodule size, and ACR TI-RADS classification in 62 participants who underwent thyroidectomy. RESULTS: Of the 62 participants, 87.1% (54/62) were women, 74.2% were < 55 years old, 95.2% had no family history of thyroid cancer, 56.5% had nodules < 2 cm in size, 62.9% were IV-B, and 69.4% were ACR TI-RADS 4. Thirty-two patients had thyroid carcinoma, and 30 had benign histology. Among all factors associated with malignancy, only ACR TI-RADS 5 classification on US was found to be statistically significant (p = 0.014), while III-B with architectural atypia cytological classification was the only one significantly associated with benign status (p = 0.004). CONCLUSION: Only a high risk of malignancy as assessed using US was able to refine the indication for molecular tests in a group of patients with indeterminate nodules. We found 85% (53/62) of III-B or IV-B thyroid nodules would benefit from available molecular diagnostic tests.
format Online
Article
Text
id pubmed-10528568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-105285682023-09-28 Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? Penna, Gustavo Cancela e Costa, Camila Teixeira Pires, Magda Carvalho Nunes, Tarcizo Afonso Arch Endocrinol Metab Original Article OBJECTIVE: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. SUBJECTS AND METHODS: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 years and ≥ 55 years, sex, family history of thyroid cancer, history of irradiation, nodule size, and ACR TI-RADS classification in 62 participants who underwent thyroidectomy. RESULTS: Of the 62 participants, 87.1% (54/62) were women, 74.2% were < 55 years old, 95.2% had no family history of thyroid cancer, 56.5% had nodules < 2 cm in size, 62.9% were IV-B, and 69.4% were ACR TI-RADS 4. Thirty-two patients had thyroid carcinoma, and 30 had benign histology. Among all factors associated with malignancy, only ACR TI-RADS 5 classification on US was found to be statistically significant (p = 0.014), while III-B with architectural atypia cytological classification was the only one significantly associated with benign status (p = 0.004). CONCLUSION: Only a high risk of malignancy as assessed using US was able to refine the indication for molecular tests in a group of patients with indeterminate nodules. We found 85% (53/62) of III-B or IV-B thyroid nodules would benefit from available molecular diagnostic tests. Sociedade Brasileira de Endocrinologia e Metabologia 2021-09-29 /pmc/articles/PMC10528568/ /pubmed/34591407 http://dx.doi.org/10.20945/2359-3997000000402 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Penna, Gustavo Cancela e
Costa, Camila Teixeira
Pires, Magda Carvalho
Nunes, Tarcizo Afonso
Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
title Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
title_full Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
title_fullStr Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
title_full_unstemmed Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
title_short Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
title_sort are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with bethesda iii or iv cytology and acr ti-rads 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528568/
https://www.ncbi.nlm.nih.gov/pubmed/34591407
http://dx.doi.org/10.20945/2359-3997000000402
work_keys_str_mv AT pennagustavocancelae aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests
AT costacamilateixeira aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests
AT piresmagdacarvalho aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests
AT nunestarcizoafonso aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests